

University of Dundee

## Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes

Rosenstock, Julio; Emral, Rifat; Sauque-Reyna, Leobardo; Mohan, Viswanathan; Trescolí, Carlos; Al Sifri, Saud

*Published in:*  
Diabetes Care

*DOI:*  
[10.2337/dc21-0393](https://doi.org/10.2337/dc21-0393)

*Publication date:*  
2021

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

### *Citation for published version (APA):*

Rosenstock, J., Emral, R., Sauque-Reyna, L., Mohan, V., Trescolí, C., Al Sifri, S., Lalic, N., Alvarez, A., Picard, P., Bonnemaire, M., Demil, N., McCrimmon, R. J. (2021). Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial. *Diabetes Care*, 44(10), 2361-2370. <https://doi.org/10.2337/dc21-0393>

### **General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.


- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

## Supplementary Material

**Supplementary Figure 1.** Diagram of multiplicity testing approach.




1-a: Non-inferiority of iGlarLixi versus BIAsp 30 on HbA<sub>1c</sub> change from baseline to Week 26; 1-b: Superiority of iGlarLixi versus BIAsp 30 on bodyweight change from baseline to Week 26; 2a: Proportion of participants reaching HbA<sub>1c</sub> target <7 % without weight gain at Week 26; 2b: Proportion of participants reaching HbA<sub>1c</sub> target <7 % without hypoglycemia, and without weight gain at Week 26; 2-c: HbA<sub>1c</sub> reduction from baseline at Week 26. Alpha will be allocated equally among both primary hypotheses (1-a and 1-b).

Test 1-a and 1-b at  $\alpha/2$  each;


- a. If 1-a is significant,  $\alpha/2$  is passed from 1-a to 1-b and 1-b is tested at the full alpha level. If significant, the full alpha is passed to test hierarchically 2-a, 2-b and 2-c at full alpha, each.

- b. If 1-a is not rejected, but 1-b is rejected at  $\alpha/2$  level, test hierarchically 2-a, 2-b at  $\alpha/2$ 
  - i. If significant, use a fallback procedure to pass  $\alpha/2$  back to 1-a and re-test 1-a at an  $\alpha$  level.
  - ii. If 1-a is rejected at the  $\alpha$  level, test 2-c at the full  $\alpha$  level. Essentially, 1-a, 1-b and 2-a and 2-b are put in a box as a gatekeeper for testing 2-c: 2-c can be tested only if 1-a, 1-b, 2-a and 2-b are all rejected.

**Supplementary Figure 2.** Participant disposition

BIAsp 30, biphasic aspart insulin 30 (30% insulin aspart and 70% insulin aspart protamine); iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and the glucagon-like peptide-1 receptor agonist, lixisenatide; ITT, intention-to-treat; PP, per protocol.

**Supplementary Figure 3.** Onset gastrointestinal adverse events reported over time (Safety population)



AE, adverse events; BIAsp 30, biphasic aspart insulin 30 (30% insulin aspart and 70% insulin aspart protamine); GI, gastrointestinal; iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and the glucagon-like peptide-1 receptor agonist, lixisenatide.

**Supplementary Table 1.** Starting doses of iGlarLixi from iGlar\*

		Previous therapy	
		iGlar ≥20 U to <30 U	iGlar ≥30 U to ≤50 U
Starting dose and pen	iGlarLixi 10–40 pen†	20 dose steps (20 U iGlar/10 µg Lixi)	
	iGlarLixi 30–60 pen†		30 dose steps (30 U iGlar/10 µg Lixi)

\*If switching from twice-daily basal insulin or insulin glargine 300 U/mL, the total daily dose previously used should be reduced by 20% to choose the starting dose of iGlarLixi; for any other BI, the same dosing should be followed as shown above for iGlar.

†Suliqua®, Sanofi, Paris, France.

BI, basal insulin; GLP-1 RA, glucagon-like 1 receptor agonist; iGlar, insulin glargine 100 U/mL; iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and the glucagon-like peptide-1 receptor agonist, lixisenatide; Lixi, lixisenatide; mcg, micrograms; OAD, oral antihyperglycemic drug; U, units.

**Supplementary Table 2.** Recommended dose adjustment algorithm for iGlarLixi

<b>Median of fasting SMPG values from the last three measurements</b>	<b>iGlarLixi* dose adjustments (U/day)</b>
>140 mg/dL (>7.8 mmol/L)	+4
>110 to ≤140 mg/dL (>6.1 to ≤7.8 mmol/L)	+2
Glycemic target: ≥80 to ≤110 mg/dL (≥4.4 to ≤6.1 mmol/L)	No change
≥60 and <80 mg/dL (≥3.3 to <4.4 mmol/L)	-2
<60 mg/dL (<3.3 mmol/L) or occurrence of ≥2 symptomatic hypoglycemic episodes or 1 severe hypoglycemic episode (requiring assistance) in the preceding week	-2 to -4 or at the investigator's discretion (or medically qualified designee)

\*The U/day refers solely to the iGlar component of iGlarLixi.

iGlar, insulin glargine 100 U/mL; iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and the glucagon-like peptide-1 receptor agonist, lixisenatide; SMPG, self-monitored plasma glucose; U, units.

**Supplementary Table 3.** Recommended dose adjustment algorithm for BIAsp 30

<b>Premeal SMPG values*</b>	<b>BIAsp 30 dose adjustments (U/day)</b>
<80 mg/dL (<4.4 mmol/L)	−2
<b>Glycemic target:</b> 80–110 mg/dL (4.4–6.1 mmol/L)	No change
111–140 mg/dL (6.2–7.8 mmol/L)	+2
141–180 mg/dL (7.9–10.0 mmol/L)	+4
>180 mg/dL (>10 mmol/L)	+6

\*Titration was based on the lowest of pre-meal SMPG values of the previous 3 days, using pre-dinner SMPG values for breakfast dose adjustment and pre-breakfast SMPG values for the dinner dose adjustment. The dose was not to be increased if hypoglycemia occurred within these days.

BIAsp 30, biphasic aspart insulin 30 (30% insulin aspart and 70% insulin aspart protamine); SMPG, self-monitored plasma glucose; U, units.



**Supplementary Table 4.** Primary and secondary efficacy endpoints (ITT population)

	<b>iGlarLixi</b> <b>(n=443)</b>	<b>BIAsp 30</b> <b>(n=444)</b>
<b>Primary efficacy endpoints</b>		
<b>HbA<sub>1c</sub>, %</b>		
Baseline, mean ± SD	8.61 ± 0.67	8.57 ± 0.65
Week 26, mean ± SD	7.26 ± 1.06	7.48 ± 0.99
Change from baseline to Week 26, mean ± SD	-1.36 ± 1.06	-1.09 ± 1.02
LS mean change from baseline to Week 26 ± SE	-1.30 ± 0.06	-1.05 ± 0.06
LS mean difference (97.5% CI)*	-0.24 (-0.41, -0.08)	
p value for non-inferiority†	p<0.001	
LS mean difference (95% CI)‡	-0.24 (-0.39, -0.10)	
p value for superiority§	p<0.001	
<b>HbA<sub>1c</sub>, mmol/mol</b>		
Baseline, mean ± SD	70.6 ± 7.3	70.2 ± 7.1
Week 26, mean ± SD	55.8 ± 11.5	58.2 ± 10.8
Change from baseline to Week 26, mean ± SD	-14.8 ± 11.6	-11.9 ± 11.1
LS mean change from baseline to Week 26 ± SE	-14.2 ± 0.7	-11.5 ± 0.7
LS mean difference (97.5% CI)*	-2.6 (-4.5, -0.9)	
p value for non-inferiority†	p<0.001	
LS mean difference (95% CI)‡	-2.6 (-4.3, -1.1)	
p value for superiority§	p<0.001	
<b>Bodyweight, kg</b>		
Baseline, mean ± SD	80.7 ± 16.5	82.2 ± 18.5
Week 26, mean ± SD	80.2 ± 16.6	83.4 ± 19.0
Change from baseline to Week 26, mean ± SD	-0.6 ± 3.1	+1.3 ± 3.1
LS mean change from baseline to Week 26 ± SE	-0.70 ± 0.20	+1.15 ± 0.20
LS mean difference (95% CI)‡	-1.86 (-2.28, -1.43)	
p value for superiority†	p<0.001	
<b>Key secondary efficacy endpoints</b>		
<b>HbA<sub>1c</sub> &lt;7 % without weight gain‡§</b>		

n (%)	122 (27.5)	55 (12.4)
Odds ratio (95% CI)	2.83 (1.98, 4.04)	
p value for superiority	p<0.001	
<b>HbA<sub>1c</sub> &lt;7 % without weight gain or hypoglycemia (plasma glucose &lt;70 mg/dL [<math>&lt;3.9</math> mmol/L])<sup>‡§</sup></b>		
n (%)	86 (19.4)	31 (7.0)
Odds ratio (95% CI)	3.40 (2.19, 5.28)	
p value for superiority	p<0.001	
<b>Other secondary efficacy endpoints</b>		
<b>FPG, mmol/L</b>		
Baseline, mean ± SD	8.37 ± 2.42	8.25 ± 2.28
Week 26, mean ± SD	7.22 ± 2.44	8.10 ± 2.84
Change from baseline to Week 26, mean ± SD	-1.12 ± 2.88	-0.16 ± 3.33
LS mean change from baseline to Week 26 ± SE	-1.07 ± 0.24	-0.16 ± 0.27
LS mean difference (95% CI)	-0.91 (-1.47, -0.34)	
<b>Total insulin dose, U<sup>§</sup></b>		
Baseline, mean ± SD	26.4 ± 6.2	33.6 ± 11.0
Week 26, mean ± SD	39.7 ± 12.0	58.2 ± 23.6
Change from baseline to Week 26, mean ± SD	13.4 ± 10.3	24.5 ± 20.8
LS mean change from baseline to Week 26 ± SE	10.6 ± 1.2	22.9 ± 1.1
LS mean difference (95% CI)	-12.2 (-14.8, -9.7)	
<b>HbA<sub>1c</sub> &lt;7 %<sup>§</sup></b>		
n (%)	187 (42.2)	141 (31.8)
Odds ratio (95% CI)	1.65 (1.25, 2.19)	

\*Endpoint was assessed at the alpha 0.025 level. <sup>†</sup>Primary efficacy endpoints, non-inferiority of HbA<sub>1c</sub> reduction was assessed using a margin of 0.3 %; <sup>‡</sup>Endpoint was assessed at the alpha 0.05 level. <sup>§</sup>Secondary endpoint. BIAsp 30, biphasic aspart insulin 30 (30% insulin aspart and 70% insulin aspart protamine); CI, confidence interval; FPG, fasting plasma glucose; iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and the glucagon-like peptide-1 receptor agonist, lixisenatide; ITT, intention-to-treat population; LS, least squares; SD, standard deviation; SE, standard error.

**Supplementary Table 5.** Sensitivity analyses of the primary and key secondary efficacy endpoints

	iGlarLixi	BIAsp 30
<b>HbA<sub>1c</sub>, %</b>		
<b>PP population</b>	<b>n=361</b>	<b>n=344</b>
LS mean difference (95% CI)*†	-0.15 (-0.29, -0.01)	
<b>MMRM analysis</b>	<b>n=443</b>	<b>n=444</b>
LS mean difference (95% CI)*†	-0.20 (-0.33, -0.07)	
<b>Penalized multiple imputation</b>	<b>n=443</b>	<b>n=444</b>
LS mean difference (95% CI)*†	-0.24 (-0.38, -0.09)	
<b>Multiple imputation for COVID-19 impacted participants</b>	<b>n=443</b>	<b>n=444</b>
LS mean difference (95% CI)*†	-0.24 (-0.39, -0.09)	
<b>ANCOVA during the on-treatment period</b>	<b>n=443</b>	<b>n=444</b>
LS mean difference (95% CI)*†	-0.20 (-0.33, -0.07)	
<b>Non-impacted by COVID-19 population</b>	<b>(n=403)</b>	<b>(n=404)</b>
LS mean difference (95% CI)*†	-0.25 (-0.41, -0.10)	
<b>Bodyweight, kg</b>		
<b>MMRM analysis</b>	<b>n=443</b>	<b>n=444</b>
LS mean difference (95% CI)	-1.87 (-2.28, -1.46)	
p value for superiority	p<0.001	
<b>Multiple imputation for COVID-19 impacted participants</b>	<b>n=443</b>	<b>n=444</b>
LS mean difference (95% CI)	-1.85 (-2.29, -1.41)	
p value for superiority	p<0.001	
<b>ANCOVA during the on-treatment period</b>	<b>n=443</b>	<b>n=444</b>
LS mean difference (95% CI)	-1.89 (-2.31, -1.47)	
p value for superiority	p<0.001	
<b>Non-impacted by COVID-19 population</b>	<b>(n=403)</b>	<b>(n=404)</b>
LS mean difference (95% CI)	-1.85 (-2.31, -1.40)	
p value for superiority	p<0.001	
<b>HbA<sub>1c</sub> &lt;7 % without weight gain</b>		
<b>Non-impacted by COVID-19 population</b>	<b>(n=403)</b>	<b>(n=404)</b>

n (%)	110 (27.3)	53 (13.1)
Odds ratio (95% CI)	2.58 (1.79, 3.73)	
p value for superiority	p<0.001	
<b>HbA<sub>1c</sub> &lt;7 % without weight gain or hypoglycemia (plasma glucose &lt;70 mg/dL [<math>&lt;3.9</math> mmol/L])</b>		
<b>Not-impacted by COVID-19 population</b>	<b>(n=403)</b>	<b>(n=404)</b>
n (%)	76 (18.9)	29 (7.2)
Odds ratio (95% CI)	3.16 (2.00, 5.00)	
p value for superiority	p<0.001	

All endpoints were assessed at the alpha 0.05 level. \*Non-inferiority objective confirmed. †Superiority objective confirmed. PP: same ANCOVA model as described for the primary analysis in the PP population (no imputation necessary since patients with missing HbA<sub>1c</sub> were excluded from PP). MMRM: MMRM under the missing at random framework was carried out using an adequate contrast at Visit 10 (Week 26), based on ITT population. Penalized multiple imputation: same ANCOVA model as described for the primary analysis with multiple imputation. A penalty of 0.3 % was added to missing HbA<sub>1c</sub> values in the iGlarLixi group only. Missing related to COVID-19 were not penalized. Multiple imputation for COVID-19 impacted participants: same ANCOVA model as described for the primary analysis in the ITT population, with separate multiple imputation process for COVID-19 impacted and non-impacted patients. Missing data in COVID-19 non-impacted patients were imputed with the same approach as primary analysis (Missing Not At Random). COVID-19 impacted patients were imputed using multiple imputation under the Missing At Random framework. ANCOVA during the on-treatment period: same ANCOVA as primary analysis in the ITT population during the on-treatment period. Only assessments before IMP discontinuation or introduction of the rescue therapy were considered in this analysis. Non-impacted by COVID-19 population: analyzed using the same methodology as primary analysis in the ITT not impacted by COVID-19 population. ANCOVA, analysis of covariance; BIAsp 30, biphasic aspart insulin 30 (30% insulin aspart and 70% insulin aspart protamine); CI, confidence interval; iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and the glucagon-like peptide-1 receptor agonist, lixisenatide; IMP, investigational medicinal product; ITT, intention-to-treat; LS, least squares; MMRM, mixed effect repeated measure; PP, per protocol.

**Supplementary Materials**

List of participating investigators

**Argentina**

Silvia Ines Orio; Gustavo Frechtel; Patricia Castaño; Jimena Coronel; Lucas Rista

**Austria**

Rudolf Prager; Slobodan Peric; Christoph Ebenbichler; Clemens Engel

**Bulgaria**

Dimitar Georgiev; Nkolay Botushanov; Yulia Kavarmova-Toneva; Ghassan Farah; Svilen Stanchev; Atanas Milev; Kiril Kirilov; Dimo Dimov; Petya Goicheva; Zahari Nikitov; Antoaneta Zlateva-Nikolaeva; Tundzhay Yozturk; Darina Vasileva; Valentina Zhelyazkova

**Czech Republic**

Dana Burdova; Marcela Szabo; Marcela Bacterova; Zuzana Kubikova; Katerina Smolenakova; Romana Urbanova; Jan Vrkoc; Tomas Spousta; Romana Urbanova; Jitka Zemanova; Silvie Lacigova; Dagmar Bartaskova; Jana Kostarova; Klaudia Halova-Karloiova; Jan Skopecek; Peter Gajdos; Tomas Edelsberger; Alica Vesela; Edit Novakova

**Greece**

Alexandros Kokkinos; Christos Sampanis; Alexandra Bargiota; Stilianos Tigas

**India**

Balamurugan Ramanathan; Paturi Rao; Rakesh Sahay; Manish Gutch; Teju Velkoor; Srinivasa Murthy; Parminder Singh; Viswanathan Mohan; Vasudha Sardesai; Farishta Faraz; Saurabh Agarwal; Pravin Supe;

**Kingdom of Saudi Arabia**

Abdulrahman Almaghamisi

**Kuwait**

Ebaa Al Ozairi; Monira Al Arouj; Abdullah Bin Nakhi; Dherar Al roudhan

**Mexico**

Ricardo Choza Romero; Leobardo Sauque Reyna; Jose Gerardo Gonzalez Gonzalez; Enrique Ortiz Jimenez; Emilia Susana Pelayo Orozco

**North Macedonia**

Bekjir Mahmudi; Dusica Stefanovska; Vjosa Xhaferi; Zulkjuflj Misimi; Cvetanka Volkanovska Ilijevska; Daniela Doneva; Hasan Taner; Ivana Trajkovska; Natasha Nedevska Minova; Iskra Bitoska Mileva; Ivica Smokovski; Katerina Adamova; Sasha Jovanovska Michevska; Tatjana Milenkovic; Ljiljana Necevska

**Romania**

Mihaela Voitec; Alina Mot; Amarin Popa; Eduard Adamescu

**Serbia**

Radivoj Kocic; Sasa Radenkovic; Jelica Bjekic-Macut; Tijana Petrović; Aleksandar Djukic; Ivana Djokic; Jelena Petrovic; Katarina Asanin; Biljana Jojic; Jelena Stojanovic; Marina Andelic Jelic; Milica Marjanovic Petkovic; Miljanka Vuksanovic; Teodora Beljic Zivkovic; Aleksandra Jotic; Ljiljana Lukic; Marija Macesic; Milica Stoilkovic; Nebojsa Lalic; Tanja Milicic; Milica Pesic; Sanja Curkovic; Sonja Kostic

**South Korea**

Kyung Mook Choi; Nan Hee Kim; Kyung Wan Min; Ji Hyun Lee; Eun-Gyoung Hong; Soon-Jib Yoo; Young Min Cho; Hyuk-Sang Kwon; Sang Yong Kim; In-Kyu Lee

**Spain**

Pedro De Pablos; Carlos Trescoli; Ana Silvia Pellitero; Daniel De Luis; Andreea Ciudin; Edelmiro Mendez; Marta Botella

**Sweden**

Hans Larnefeldt; Gunnar Strömblad; Ingemar Torstensson

**Taiwan**

Ching-Chu Chen; Shu-Yi Wang; Kai-Jen Tien; Chen-Ling Huang; Shuen-Fu Weng; Chii-Min Hwu; Horng-Yih Ou

**Turkey**

Fahri Bayram; Adil Begüm Bahçecioğlu Mutlu; Rıfat Emral; Fatma Nur Korkmaz; Abdurrahman Çömlekçi; Başak Saydam; Cem Adıyaman; Tevfik Demir; Canan Ersoy; Soner Cander; Emre Gezer; Zeynep Cantürk; Cem Onur Kirac; Levent Kebapçılar; Suleyman Ipekci; Gulay Simsek Bagir; Okan Sefa Bakiner;